We are working from home under lockdown. Our team is continuously tracking the impact of COVID-19 across different industries and we will incorporate those insights in our reports. For any specific query, mail us at [email protected]
In Vitro Diagnostic Testing Market | Covid-19 Impact Analysis
This report, from Stratview Research, studies the clinical diagnostics market over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Burning Questions This Report Will Answer:
In IVD market oncology is one of the most sought-after segments by the manufacturers. Non-invasive cancer testing is expected to be a hot market in 2019. Qiagen, one of the global MNC, has been pioneering the use of liquid biopsy-based companion diagnostics as a less-invasive option to complement surgical biopsies for genomic profiling of cancers. In the infectious diseases segment, most of the currently available tests detect a single pathogen, or an antibiotic resistance gene. However, if a patient presents with general symptoms of a respiratory infection, or with symptoms of a gastrointestinal infection or some other type of infection, there are several different pathogens that may have caused the infection. However, syndromic testing is soon becoming a reality where multiple pathogens can be detected, increasing the chances of detection, bringing down the cost of testing and directly impacting the DALY of patients.
Over the years, the market has been driven by big names of IVD such as Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific (US) who have been bending the rules of the game. However, in recent years, there are several market disruptors who are openly challenging the monopoly of these players and determined to bring down the cost of care and introduce user friendly and cost effective services and IVD equipment in the market.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
The global clinical diagnostics market (IVD) is segmented into the following categories:
By Type of Demand for Sample
By Testing Facility
With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].